2023 World Conference on Lung Cancer (Posters)-P2.09. QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review

P2.09. QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of a targeted literature review that aimed to determine the incidence and mortality of QT-interval prolongation (QTp) and Torsades de Pointes (TdP) in patients with non-small cell lung cancer (NSCLC) who received epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The review included both electronic and manual searches to identify relevant studies. The populations assessed were patients with any cancer type treated with TKIs and patients with NSCLC treated with specific EGFR TKIs. The outcomes of interest were the incidence and mortality of QTp and TdP. <br /><br />The results of the review showed that changes in heart rhythm, such as QTp and TdP, can occur with some cancer treatments, including EGFR TKIs, even in patients without a relevant clinical history. The incidence and mortality rates of QTp and TdP varied among studies, with incidence rates ranging from 0% to 33.7% in patients with any type of cancer treated with TKIs, and from 0% to 27.8% in patients with NSCLC treated with EGFR TKIs. However, no deaths due to TdP were reported in any studies. <br /><br />The review also identified specific EGFR TKIs that have been associated with QTp events, such as afatinib and osimertinib. The US prescribing information for these TKIs provided information on the incidence of QTp, with rates ranging from 0% to 25% for afatinib and from 0% to 27.8% for osimertinib.<br /><br />Overall, the review highlights the importance of monitoring patients receiving EGFR TKIs for signs of cardiotoxicity, particularly changes in heart rhythm. There are some limitations to the review, including the language restriction to English publications and the variability in outcome definitions and criteria used across studies. Future directions for research include the development of standardized definitions of QTp and improved monitoring methods for QTp and TdP in patients with cancer.

Asset Subtitle

Bilal Khokhar

Meta Tag

Speaker Bilal Khokhar

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

incidence

mortality

QT-interval prolongation

Torsades de Pointes

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR

tyrosine kinase inhibitors

cancer treatments